Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma With a Dose-Finding Lead-In

NCT02254551 is registered in ClinicalTrials.gov with SCRI Development Innovations, LLC as lead sponsor.

NCT NCT02254551
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02254551 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma With a Dose-Finding Lead-In
Lead sponsor
SCRI Development Innovations, LLC
Phase
Phase 2
Overall status
Terminated
Start date
January 31, 2015
Completion date
October 31, 2015
Enrollment
7 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma